Pfizer And Lpath To Partner On Antibody For Wet Age-Related Macular Degeneration
This article was originally published in The Pink Sheet Daily
Option deal provides $14 million upfront plus cost-sharing arrangement for previously cash-strapped biotech.
You may also be interested in...
The San Diego biotech gets clearance from regulatory authorities to restart Phase II trials for its lead compound after a clinical hold delayed progress.
Initial public offerings by life sciences companies spanned the alphabet over the past two weeks, but each of three IPOs had one common factor - significant discounts in opening share prices.
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.